Blend Therapeutics Inc., a Watertown, Mass.-based biopharmaceutical company, has raised $16m in Series B financing.
The round was led by NanoDimension, with participation from existing investors Flagship Ventures and New Enterprise Associates.
The company intends to use the capital to expand product and business development teams and to advance its lead programs through studies to enable filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA).
Led by Mark Iwicki, President and CEO, Blend Therapeutics develops proprietary molecules for oncology fueled by Dr. Omid Farokhzad of the Brigham and Women’s Hospital (BWH)–Harvard Medical School (HMS), and Dr. Robert Langer and Dr. Stephen J. Lippard of Massachusetts Institute of Technology (MIT). Blend has attracted top-tier investors including Flagship Ventures, NanoDimension, and New Enterprise Associates.